- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy
A key opinion leader examines the November 2022 guidelines for managing Friedreich's ataxia, discusses the first FDA-approved therapy for the condition, and explains how this treatment is integrated into current disease management strategies.
EP: 1.Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities
EP: 2.Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy
EP: 3.Engaging mFARS Scale to Monitor Friedreich Ataxia Progression
EP: 4.Managing Adverse Events in Novel Friedreich’s Ataxia Therapy
EP: 5.Examining Trial Data on Omaveloxolone Efficacy
EP: 6.Promising Therapy Approaches for Advanced Friedreich Ataxia
EP: 7.Friedreich Ataxia: Looking Forward at the Treatment Landscape
EP: 8.Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia
EP: 9.Diagnosis of Friedreich Ataxia
EP: 10.Impact of Friedreich Ataxia on Quality of Life
EP: 11.Clinical Utility of the Modified Friedreich Ataxia Rating Scale
EP: 12.Comorbidities and Complications Associated With Friedreich Ataxia
EP: 13.Challenges Associated With Friedreich Ataxia
EP: 14.Future Considerations for Friedreich Ataxia
- What are some of the key recommendations outlined in the guidelines for managing FA published in November 2022?
- Could you elaborate on the significance of omaveloxolone as the first FDA-approved therapy for Friedreich’s ataxia and how you incorporate this treatment into your disease management regimen? Since the approval of omaveloxolone, what has been the impact on the management of advanced stages of the disease and life expectancy in FA patients?
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
